Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2017 | How are drug development and clinical trials changing?

Anas Younes • 29 Mar 2017
BSH 2017

Anas Younes, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses changes in drug development and clinical trials at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He explains how hurdles for testing drugs from different companies are disappearing, allowing combination therapies to be trialed. Prof. Younes also discusses how the use of mechanism-based approaches could address the 90% failure rate in the pharmaceutical industry and result in lower costs for future treatments.

More from Anas Younes

Fimepinostat with venetoclax in R/R lymphoma
1:01
Fimepinostat with venetoclax in R/R lymphoma
Anas Younes • 7 Dec 2019
Atezolizumab plus R-CHOP in DLBCL: encouraging results
1:27
Atezolizumab plus R-CHOP in DLBCL: encouraging results
Anas Younes • 7 Dec 2019
Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma
1:42
Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma
Anas Younes • 7 Dec 2019
Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
2:55
Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
Anas Younes • 6 Dec 2018

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals